News BMS bolts on SystImmune bispecific ADC in $8.4bn deal The litany of big-ticket deals involving antibody-drug conjugates shows no sign of ending.
News BioNTech flashes the cash, adding tumour drug in $1bn deal Fresh from slashing its predictions for COVID-19 vaccine sales this year, mRNA specialist BioNTech has used some of its extensive cash reserves to bolster its pipeline in
Oncology Pfizer’s bispecific elranatamab and future oncological care Pfizer announced that the FDA granted Priority Review for its BLA for bispecific elranatamab.
Oncology JP Morgan 2023 – Adi Hoess pharmaphorum editor-in-chief Jonah Comstock joins Adi Hoess, CEO of Affimed, at the Zeppelin Hotel in San Francisco, to learn about
Oncology In pursuit of a cure for cancer: An ASCO 2025 discussion wit... Dr Danny Nguyen, medical oncologist and haematologist at the City of Hope Orange County, spoke with pharmaphorum at ASCO 2025.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
